根据经验,“Therapeutic Advances in Medical Oncology”的审稿周期一般为15周。 10、版面费 “Therapeutic Advances in Medical Oncology”是一本开放获取(OA)期刊,根据官方信息,其开放获取版面费为2800美元。这意味着作者支付费用后,其发表的文章将对所有人开放,可以免费阅读和下载。 11、网址信息 期刊官网:https://...
研究方向:ONCOLOGY 是否预警:否 创刊时间:2009 H-index:34 出版周期:Continuous publication 出版语言:English 年发文量:194 文章自引率:0.02... 投稿咨询加急服务 期刊简介 医学肿瘤学的治疗进展(Therapeutic Advances In Medical Oncology)是一本由SAGE Publications Inc.出版的一本ONCOLOGY学术刊物,主要报道ONCOLOGY相...
出版周期:Continuous publication 出版国家或地区:ENGLAND 创刊:2009 影响因子:4.3 是否预警:否 语言:English 是否OA开放访问:开放 研究方向:ONCOLOGY 杂志简介 SCIE期刊 学科领域:ONCOLOGY Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, ...
Therapeutic Advances in Medical Oncology的审稿周期平均3-4个月左右接受，当然有的快一些，有的相对慢一些。整体来说，发文速度比较快。：作为一本开放获取期刊，版面费为2200美元，约合人民币14900元。肿瘤学期刊 Therapeutic Advances in Medical Oncology 是一本领先的开放获取的同行评审的国际期刊，Ther...
通过对比Therapeutic Advances in Medical Oncology期刊 直接录用影响因子分值、sitescore值、审稿周期、投稿录用率等指标,以图表的形式直观展现Therapeutic Advances in Medical Oncology期刊 直接录用各个指标的对比趋势图,让您一目了然的看到各个期刊的优缺点,快速锁定目标期刊进行投稿,节省投稿周期!
Therapeutic Advances in Medical Oncology THER ADV MED ONCOL 最新影响因子:5.485 期刊ISSN:1758-8340 CiteScore:5.79 出版周期: 是否OA:YES 出版年份:0 期刊官方网址:http://tam.sagepub.com/ 自引率:0.80% 研究方向:ONCOLOGY- 出版地区:ENGLAND SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展...
投稿方式 (1)投稿作者请与吴大维教授(wumingshi-117@163.com)联系。 (2)投稿须知等信息请查阅《Therapeutic Advances in Medical Oncology》杂志官网:https://journals.sagepub.com/home/tam 关于《Therapeutic Advances in Medical Oncology》杂志T...
Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an ...
Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an ...